Gene therapy using adeno-associated virus (AAV) vectors offers a transformative approach for treating Duchenne muscular dystrophy (DMD), a genetic disorder caused by dystrophin deficiency. Achieving therapeutic levels of dystrophin expression in large muscle masses, however, remains a significant challenge. A recent study published in Molecular Therapy: Methods & Clinical Development by researchers from Bristol Myers Squibb utilized non-human primates (NHPs) to provide critical insights into the efficacy and specificity of AAV-based therapies. The study offers valuable guidance for advancing these therapies to human clinical trials, synthesizing findings from key research efforts that focus on serotype performance, biodistribution, expression profiles, and therapeutic implications.
AAV8 as the optimal serotype for systemic gene therapy in DMD
The comparison of AAV serotypes—AAV5, AAV8, and AAV9—highlights their differential efficiency in transducing skeletal and cardiac muscles. A single-dose study in NHPs using vectors packaged with a C5-12-microdystrophin-Flag construct revealed:
- AAV8 Superiority: AAV8 emerged as the most efficient serotype, achieving ~20% of wild-type dystrophin protein levels in skeletal muscles and transducing ~40% of skeletal muscle fibers and ~15% of left ventricular cardiomyocytes.
- AAV9 Performance: AAV9 demonstrated moderate efficacy in skeletal muscles but underperformed relative to AAV8 in cardiac tissues, even at higher doses.
- AAV5 Characteristics: AAV5 exhibited lower transduction efficiency but presented a promising safety profile due to reduced global prevalence of neutralizing antibodies (nAbs).
These findings underscore AAV8 as the optimal serotype for systemic gene therapy in DMD.
Skeletal muscles demonstrated more robust AAV transduction and expression than cardiac tissues
Skeletal muscles exhibited robust transduction and expression, with vector genome (VG) levels observed in a narrow range of 1–2×10⁵ vg/μg genomic DNA. mRNA expression exceeded 1×10⁶ copies/μg RNA, correlating with a 3–4 fold increase in protein levels. Among the treated NHPs, those receiving AAV8 demonstrated the highest dystrophin expression, particularly in the diaphragm, quadriceps, and forearm. In contrast, cardiac muscle expression was less efficient compared to skeletal muscles. Although the highest VG levels were detected in the atria, this did not translate to substantial protein expression. For both mRNA and protein levels, AAV8 and AAV5 outperformed AAV9 in the ventricles, with AAV8 achieving slightly higher microdystrophin expression.
C5-12 promoter demonstrated exceptional selectivity for striated muscles, with negligible expression in off-target tissue
The synthetic C5-12 promoter demonstrated high specificity for striated muscles, with minimal off-target expression observed in non-muscle tissues, including the liver and kidneys. It enabled efficient expression in both fast and slow muscle fibers, which is an important consideration for therapeutic transgene activity across diverse muscle types. While the promoter was effective in skeletal muscles, it exhibited lower activity in cardiac tissues, highlighting the need for further optimization.
Challenges in cardiac expression: Why cardiac expression is needed?
Achieving sufficient microdystrophin expression in cardiac tissues is crucial for addressing the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). However, despite robust outcomes in skeletal muscles, cardiac expression presents several challenges. Low translation efficiency is a significant issue, as mRNA levels in cardiac tissues do not correlate well with protein expression. Additionally, differences in tropism among AAV serotypes, particularly between atria and ventricles, complicate efficient targeting of cardiac tissues. Furthermore, the activity of the C5-12 promoter appears to be less effective in cardiac tissues, emphasizing the need for further optimization to improve therapeutic outcomes in the heart.
Toxicokinetics and immune screening highlight sustained delivery to target tissues and emphasize the importance of neutralizing antibody (nAb) screening
Plasma toxicokinetics revealed distinct clearance profiles for the tested AAV serotypes. AAV5 showed rapid clearance from plasma, with most vector genomes (VG) eliminated within 24 hours. In contrast, AAV8 and AAV9 exhibited extended circulation, remaining in plasma for over 48 hours. This prolonged persistence supports the sustained delivery of vectors to target tissues, which is critical for achieving therapeutic expression levels.
Immune screening demonstrated that pre-existing neutralizing antibodies (nAbs) significantly impacted therapy efficacy. Only NHPs with low nAbs for all three serotypes were selected for the study, ensuring compatibility with AAV-based treatments. Post-treatment analysis revealed serotype-specific immune responses with minimal cross-reactivity, except in one case where an AAV8-treated animal developed nAbs to AAV9. These findings highlight the crucial role of nAb screening in optimizing therapeutic outcomes for AAV-mediated gene therapy.
Therapeutic Implications
The systemic delivery of AAV8-C5-12-microdystrophin at a dose of 1.18 × 10^14 vg/kg offers several promising implications for treating Duchenne muscular dystrophy:
- Therapeutic Protein Levels: The study achieved approximately 20% of wild-type dystrophin levels in skeletal muscle. This is particularly significant because previous research has shown that expression levels as low as 15% of normal dystrophin can potentially prevent dystrophic pathology, depending on the functionality of the truncated protein.
- Safety Profile: No significant adverse effects related to vector administration were observed, with unremarkable hematology, serum chemistry, and pathology findings. This supports the potential safety of the tested doses for future clinical applications.
- Species-Specific Insights: The study highlights critical differences between non-human primates (NHPs) and rodent models, providing more accurate dose projections for human trials. This underscores the importance of large animal studies in translating gene therapies to the clinic.
- Potential for Clinical Translation: The combination of achieving therapeutic protein levels and a favorable safety profile suggests that this approach could be a viable candidate for clinical trials in DMD patients.
However, the authors note that there is still significant room for improvement, particularly in achieving more uniform expression across a higher percentage of muscle fibers. This indicates that while the current results are promising, further optimization may be necessary to maximize the therapeutic potential of this approach.
Future Directions
To address the current limitations and enhance the efficacy of AAV-based therapies, future research should focus on several key areas. Enhancing transduction efficiency is crucial, and developing strategies to increase the percentage of muscle fibers expressing the microdystrophin protein will be pivotal. Capsid engineering, such as designing novel capsids with improved muscle tropism and reduced immunogenicity, could play a significant role in achieving this goal. Additionally, refining promoters to ensure balanced activity across skeletal and cardiac tissues can help optimize therapeutic outcomes.
Dose optimization is another critical area of focus. Future studies should explore whether higher doses can achieve more uniform expression without compromising safety, while also establishing precise relationships between vector dose, tissue distribution, and transgene expression. Long-term studies are needed to investigate the durability of expression and the long-term safety profile in non-human primates (NHPs), ensuring the sustained effectiveness of the therapy.
Lastly, functional studies should assess how achieved dystrophin levels impact muscle function and disease progression in animal models. Strategies for immune modulation, including approaches to overcome pre-existing immunity to AAV vectors, will also be vital in expanding the applicability of AAV-based therapies to a broader patient population. Together, these research priorities can guide the development of safer and more effective treatments for Duchenne muscular dystrophy and other muscle disorders.
Conclusion
This study highlights the transformative potential of AAV-mediated gene therapy for Duchenne muscular dystrophy. The superior performance of AAV8, coupled with the muscle-specific activity of the C5-12 promoter, offers a promising pathway for achieving therapeutic transgene expression. However, challenges in cardiac expression and pre-existing immunity remain critical hurdles. By addressing these limitations through innovative vector design and translational research, AAV-based therapies can revolutionize the treatment landscape for muscular dystrophies.
Reference
Liu, Mengping et al. (2025) Systemic Delivery of AAV5, AAV8, and AAV9 Packaging a C5-12-Micro-dystrophin Flag Expression Cassette in Non-Human Primates. Molecular Therapy: Methods & Clinical Development. Molecular Therapy Methods & Clinical Development, Volume 0, Issue 0, 101411. DOI: 10.1016/j.omtm.2025.101411
MarinBio Publications and Presentations on Gene Therapy
American Society of Hematology (ASH) Annual Meeting 2024
In Vitro and Cell-Based Assays Used in This Study
To evaluate the efficacy, specificity, and safety of adeno-associated virus (AAV)-based microdystrophin gene therapy, the study employed a series of in vitro and cell-based assays. These assays were pivotal in assessing the biodistribution, transduction efficiency, and protein expression levels of the microdystrophin-Flag construct in non-human primates (NHPs). The comprehensive approach provided valuable insights into the therapeutic potential of AAV vectors in treating Duchenne muscular dystrophy (DMD).
Neutralizing Antibody (nAb) Assay
The cell-based luciferase assay was used to detect pre-treatment and post-treatment nAbs against AAV5, AAV8, and AAV9. This assay helped identify NHPs with low pre-existing immunity, ensuring minimal interference with AAV delivery and monitoring serotype-specific immune responses post-administration.
Total Antibody (tAb) Assay
An enzyme-linked immunosorbent assay (ELISA) quantified total antibodies against AAV capsids in serum. This assay complemented the nAb assay, helping evaluate the immunogenicity of each AAV serotype and confirming serotype-specific immune reactions.
Vector Genome (VG) Quantification by qPCR
Quantitative PCR (qPCR) measured VG copies in plasma and tissue samples. This assay assessed the biodistribution of the AAV vectors, providing critical data on tissue uptake and systemic circulation.
mRNA Quantification by qPCR
Reverse transcription-qPCR measured microdystrophin-Flag mRNA levels in tissues. This assay evaluated transcriptional activity across different tissues, indicating promoter specificity and active gene transcription.
Microdystrophin-Flag Protein Quantification
Two distinct methods quantified protein expression. The Meso Scale Discovery (MSD)-ELISA detected microdystrophin-Flag levels in tissue lysates, while liquid chromatography-mass spectrometry (LC-MS) quantified microdystrophin-Flag as a percentage of endogenous dystrophin, particularly in skeletal and cardiac muscles. These assays provided insights into protein translation efficiency and therapeutic protein levels.
Immunofluorescence Assay
Confocal microscopy visualized the localization and distribution of microdystrophin-Flag protein in muscle tissues. It assessed the proportion of muscle fibers expressing the transgene and its proper localization to the sarcolemma, confirming functional integration.
Toxicokinetics in Plasma
qPCR tracked VG clearance from plasma at various time points post-administration. This assay offered insights into the persistence of AAV vectors in circulation, informing systemic exposure and clearance rates.
Key Insights from the Assays
The assays collectively demonstrated that AAV8 outperformed other serotypes, achieving superior mRNA and protein expression levels in skeletal muscles. The C5-12 promoter showed high specificity for striated muscles, with minimal off-target effects and no significant pathological findings, confirming the safety of the vectors. Additionally, biodistribution data revealed active transcription and translation predominantly in muscle tissues, underscoring the targeted nature of the therapy. Together, these findings provide a robust framework for evaluating the therapeutic potential of AAV-delivered microdystrophin in NHPs, a translationally relevant model for advancing DMD gene therapy.
Gene Therapy Assay Services Offered by MarinBio
Contact us at 415.883.8000 or email us at info@marinbio.com with any questions about in vitro or cell based assays for gene therapy development.
Molecular Biology & qPCR
- Viral vector & plasmid construction (research grade & small-scale GMP grade)
- Infectious genome and vector genome titers
- Residual host DNA quantitation
ELISA & Immunoassays
- Protein titer by ELISA
- Residual host protein quantitation
- Pharmacokinetics (PK) assays
- Pharmacodynamics (PD) assays
Cell-Based Assays for gene therapy drugs
- Gene-specific functional assays
- Reporter assays
- Development of customized reporter assays
Flow cytometry assays for gene therapy products
- Infectious titer by flow cytometry
- Gene delivery and potency assays
Immunogenicity assays
- ADCC, Antibody-Dependent Cellular Cytotoxicity bioassays
- ADA, Anti-Drug Antibody inhibiting drug action
- T-cell assays: Peripheral blood mononuclear cell (PBMC)- and dendritic cell (DC)- based assays.
- Cytokine Release Syndrome Assay
- Natural Killer (NK) Cell Assay
- Phagocytosis Assay
